{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:33:38Z","timestamp":1791894818649,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clinthera.2023.01.001","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T07:45:41Z","timestamp":1674200741000},"page":"151-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System"],"prefix":"10.1016","volume":"45","author":[{"given":"Hui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-2215","authenticated-orcid":false,"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00432-020-03448-8","article-title":"Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers","volume":"147","author":"Yamamoto","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0003","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0004","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Mizuno","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2957\/kanzo.60.83","article-title":"A case of non-comatose acute hepatic failure: an immune-related adverse event due to sequential administration of nivolumab and ipilimumab","volume":"60","author":"Yamamoto","year":"2019","journal-title":"Kanzo"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0008","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1038\/ctg.2017.28","article-title":"Targeting the vasculature in hepatocellular carcinoma treatment: starving vs normalizing blood supply","volume":"8","author":"Liu","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107832","article-title":"Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)","volume":"117","author":"Kamitaki","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12531","article-title":"Introduction to checkpoint inhibitors and cancer immunotherapy","volume":"276","author":"Sharpe","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11901-018-0408-8","article-title":"Knowns and unknowns: the safety and efficacy of cancer immunotherapy in chronic liver disease","volume":"17","author":"Chascsa","year":"2018","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0013","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s12325-019-01034-0","article-title":"Survival analysis in patients with metastatic Merkel cell carcinoma treated with avelumab","volume":"36","author":"Lanitis","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000674","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial","volume":"8","author":"D'Angelo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00262-014-1609-9","article-title":"CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic\/target therapy?","volume":"64","author":"Calabr\u00f2","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0017","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0018","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1007\/s12325-021-01796-6","article-title":"Durvalumab plus tremelimumab in solid tumors: a systematic review","volume":"38","author":"Arru","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100561","article-title":"Hepatic immune-mediated adverse effects of immune checkpoint inhibitors: analysis of real-life experience","volume":"26","author":"da Silva","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0021","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab vs ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0022","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0023","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-208102","article-title":"Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy","volume":"2015","author":"Ahmed","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0025","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0026","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of immune checkpoint inhibitor-mediated liver injury","volume":"11","author":"Shojaie","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0027","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2023.01.001_bib0028","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/imt-2021-0191","article-title":"Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma","volume":"14","author":"Swanson","year":"2022","journal-title":"Immunotherapy"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:09Z","timestamp":1758963489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0149291823000206"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}